YU35401A - POSTUPCI I PREPARATI ZA USPOSTAVLJANJE UJEDNAČENE STABILNOSTI PROTEINA IZ p53 FAMILIJE - Google Patents
POSTUPCI I PREPARATI ZA USPOSTAVLJANJE UJEDNAČENE STABILNOSTI PROTEINA IZ p53 FAMILIJEInfo
- Publication number
- YU35401A YU35401A YU35401A YU35401A YU35401A YU 35401 A YU35401 A YU 35401A YU 35401 A YU35401 A YU 35401A YU 35401 A YU35401 A YU 35401A YU 35401 A YU35401 A YU 35401A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- protein
- family
- methods
- compositions
- restoring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Pronalazak je iz oblasti tretmana raka. Naročito, ovaj pronalazak obezbedjuje farmaceutska jedinjenje sposobna da medjusobno deluju sa mutant i ne-mutant oblicima proteina koji se odnose na rak tako da mutant protein pojačava kapacitet za ispravno medjusobno delovanje sa drugim makromolekulima, čime se uspostavljaju ili stabilišu svi ili deo njihovih aktivnosti neobradjenog tipa. Regulacioni proteini uključuju članove iz p53 protein familije takve kao, na primer p53, p63 i p73. Jedinjenja iz pronalaska su korisna za tretman raka. Postupci za ekranizovanje takvih farmakoloških jedinjenja su takodje obezbedjeni.[The invention provides pharmaceutical non-peptidic organic compounds capable of interacting with a functionally defective form of a mutant or a wild-type tumor suppressor protein of the p53 family (such as p53, p63 or p73). The interaction allows stabilization or folding of the protein in a functional conformation, thereby restoring all or part of its wild-type normal activity. More particularly said compounds interact with the DNA binding domain of p53 family proteins, are acridine, quinoline, quinazoline or phenothiazine derivatives, and are used in cancer therapy. Also provided are methods for screening such pharmacological compounds.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11054298P | 1998-12-02 | 1998-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU35401A true YU35401A (sh) | 2005-07-19 |
Family
ID=22333594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU35401A YU35401A (sh) | 1998-12-02 | 1999-12-01 | POSTUPCI I PREPARATI ZA USPOSTAVLJANJE UJEDNAČENE STABILNOSTI PROTEINA IZ p53 FAMILIJE |
Country Status (25)
Country | Link |
---|---|
US (1) | US20020048271A1 (sh) |
EP (1) | EP1137418A2 (sh) |
JP (2) | JP2002531396A (sh) |
KR (1) | KR20010086073A (sh) |
CN (1) | CN1329493A (sh) |
AP (1) | AP2001002153A0 (sh) |
AU (1) | AU1290700A (sh) |
BG (1) | BG105599A (sh) |
BR (1) | BR9915940A (sh) |
CA (1) | CA2350597A1 (sh) |
EA (1) | EA003326B1 (sh) |
EE (1) | EE200100302A (sh) |
HK (1) | HK1041644A1 (sh) |
HR (1) | HRP20010414A2 (sh) |
HU (1) | HUP0201215A2 (sh) |
ID (1) | ID29061A (sh) |
IL (1) | IL143094A0 (sh) |
IS (1) | IS5943A (sh) |
NO (1) | NO20012737L (sh) |
OA (1) | OA11722A (sh) |
PL (1) | PL348310A1 (sh) |
TR (1) | TR200101549T2 (sh) |
WO (1) | WO2000032175A2 (sh) |
YU (1) | YU35401A (sh) |
ZA (1) | ZA200104210B (sh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
AU2002310497A1 (en) * | 2001-06-20 | 2003-01-08 | Caprion Pharmaceuticals Inc. | Protein aggregation assays and uses thereof |
EP1414846A2 (en) * | 2001-08-10 | 2004-05-06 | Medical Research Council | Molecule |
WO2004034013A2 (en) * | 2002-05-06 | 2004-04-22 | Colorado State University Research Foundation | Genotoxicity analysis |
WO2004030671A2 (en) * | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
EP1470818B1 (en) * | 2003-04-25 | 2006-07-26 | Neuro3D | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns |
US6970791B1 (en) * | 2003-05-23 | 2005-11-29 | Verachem, Llc | Tailored user interfaces for molecular modeling |
AU2004253967B2 (en) * | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
EP1687275A4 (en) * | 2003-11-21 | 2009-01-14 | Merck & Co Inc | PYRIDINE-4-YLAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF NEUROPATHIC PAIN |
WO2005061001A1 (ja) * | 2003-12-24 | 2005-07-07 | Locomogene, Inc. | 癌の抑制方法 |
JPWO2005061007A1 (ja) * | 2003-12-24 | 2007-07-12 | 学校法人 聖マリアンナ医科大学 | 癌の抑制方法 |
EP1781293A1 (en) * | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
US20070015774A1 (en) * | 2005-07-15 | 2007-01-18 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
ATE470665T1 (de) | 2006-03-22 | 2010-06-15 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
NZ546477A (en) * | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
MY162844A (en) | 2006-07-10 | 2017-07-31 | The Trustee Of Columbia Univ In The City Of New York | Anti-cocaine compositions and treatment |
WO2008155441A1 (en) * | 2007-06-20 | 2008-12-24 | Marikki Laiho | Activators and therapeutic applications thereof |
BRPI0813556A2 (pt) * | 2007-07-10 | 2015-06-16 | Univ Columbia | Termoestabilização de proteínas |
TW200922557A (en) | 2007-08-06 | 2009-06-01 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 |
KR101730407B1 (ko) | 2009-02-04 | 2017-04-26 | 얀센 파마슈티카 엔.브이. | 항암제로서의 인돌 유도체 |
WO2011127406A2 (en) * | 2010-04-09 | 2011-10-13 | The Brigham And Women's Hospital, Inc. | Acridines as inhibitors of haspin and dyrk kinases |
US9221760B2 (en) | 2011-05-09 | 2015-12-29 | Van Andel Research Institute | Autophagy inhibitors |
WO2013043744A2 (en) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
CN102660257B (zh) * | 2012-05-22 | 2013-11-27 | 南京邮电大学 | 吩噻嗪基喹唑啉类荧光离子探针及其应用 |
PL3201234T3 (pl) | 2014-09-30 | 2019-04-30 | Diadem S R L | Przeciwciało wiążące liniowy epitop ludzkiego p53 i zastosowania diagnostyczne tego przeciwciała |
CN105418501B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
CN105399671B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
CN105399670B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途 |
WO2017134671A1 (en) | 2016-02-04 | 2017-08-10 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
US10138219B2 (en) * | 2016-02-19 | 2018-11-27 | Pmv Pharmaceuticals | Methods and compounds for restoring mutant p53 function |
CN109694358B (zh) * | 2019-01-23 | 2022-02-08 | 广西师范大学 | 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用 |
KR20220070255A (ko) * | 2019-09-23 | 2022-05-30 | 피엠브이 파마슈티컬스 인코포레이티드 | 돌연변이체 p53 기능을 회복시키기 위한 방법 및 화합물 |
CN116096704A (zh) | 2020-06-24 | 2023-05-09 | 皮姆维制药公司 | 用于治疗癌症的组合疗法 |
US20210405056A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Methods for detecting mutant p53 function |
GB202111035D0 (en) * | 2021-07-30 | 2021-09-15 | Vestlandets Innovasjonsselskap As | Therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
CA2185116A1 (en) * | 1994-03-08 | 1995-09-14 | Thomas P. Wallace | Recombinant humanized anti-fb5 antibodies |
JPH10510986A (ja) * | 1994-12-13 | 1998-10-27 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | メタロプロテイナーゼ−4のヒト組織インヒビター |
US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
EP0959877A4 (en) * | 1996-04-10 | 2000-08-23 | Univ California | CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS |
US6270954B1 (en) * | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
DE19624154A1 (de) * | 1996-06-18 | 1998-01-08 | Hoechst Ag | Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung |
US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
HUP0000210A3 (en) * | 1996-08-28 | 2001-07-30 | Procter And Gamble Co Cincinna | Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
US6387903B1 (en) * | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
FI105554B (fi) * | 1998-05-13 | 2000-09-15 | Galilaeus Oy | Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit |
US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
EP1104761B1 (en) * | 1998-08-12 | 2004-10-13 | Daiichi Pure Chemicals Co., Ltd. | Fluorescent labelling reagents |
SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6406699B1 (en) * | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
WO2001028550A1 (en) * | 1999-10-15 | 2001-04-26 | Mayo Foundation For Medical Education And Research | Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia |
US6372785B1 (en) * | 2000-05-04 | 2002-04-16 | Keith Chan, President Globoasia, Llc | Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon |
US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6391916B1 (en) * | 2000-07-21 | 2002-05-21 | The Hong Kong University Of Science And Technology | Enediyne derivatives |
-
1999
- 1999-12-01 EE EEP200100302A patent/EE200100302A/xx unknown
- 1999-12-01 EP EP99956270A patent/EP1137418A2/en not_active Withdrawn
- 1999-12-01 JP JP2000584871A patent/JP2002531396A/ja active Pending
- 1999-12-01 CN CN99814010A patent/CN1329493A/zh active Pending
- 1999-12-01 AP APAP/P/2001/002153A patent/AP2001002153A0/en unknown
- 1999-12-01 CA CA002350597A patent/CA2350597A1/en not_active Abandoned
- 1999-12-01 YU YU35401A patent/YU35401A/sh unknown
- 1999-12-01 PL PL99348310A patent/PL348310A1/xx unknown
- 1999-12-01 AU AU12907/00A patent/AU1290700A/en not_active Abandoned
- 1999-12-01 OA OA1200100136A patent/OA11722A/en unknown
- 1999-12-01 ID IDW00200101178A patent/ID29061A/id unknown
- 1999-12-01 TR TR2001/01549T patent/TR200101549T2/xx unknown
- 1999-12-01 EA EA200100502A patent/EA003326B1/ru not_active IP Right Cessation
- 1999-12-01 WO PCT/IB1999/001916 patent/WO2000032175A2/en not_active Application Discontinuation
- 1999-12-01 HU HU0201215A patent/HUP0201215A2/hu unknown
- 1999-12-01 BR BR9915940-6A patent/BR9915940A/pt not_active IP Right Cessation
- 1999-12-01 KR KR1020017006830A patent/KR20010086073A/ko not_active Application Discontinuation
- 1999-12-01 IL IL14309499A patent/IL143094A0/xx unknown
-
2001
- 2001-05-15 IS IS5943A patent/IS5943A/is unknown
- 2001-05-23 ZA ZA200104210A patent/ZA200104210B/en unknown
- 2001-05-23 US US09/863,976 patent/US20020048271A1/en not_active Abandoned
- 2001-05-29 HR HR20010414A patent/HRP20010414A2/hr not_active Application Discontinuation
- 2001-06-01 NO NO20012737A patent/NO20012737L/no not_active Application Discontinuation
- 2001-06-14 BG BG105599A patent/BG105599A/xx unknown
-
2002
- 2002-05-04 HK HK02103378.4A patent/HK1041644A1/zh unknown
-
2006
- 2006-01-06 JP JP2006001475A patent/JP2006166920A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2000032175A2 (en) | 2000-06-08 |
HRP20010414A2 (en) | 2002-06-30 |
EP1137418A2 (en) | 2001-10-04 |
EE200100302A (et) | 2002-08-15 |
ID29061A (id) | 2001-07-26 |
US20020048271A1 (en) | 2002-04-25 |
AP2001002153A0 (en) | 2001-06-30 |
WO2000032175A3 (en) | 2000-08-03 |
EA003326B1 (ru) | 2003-04-24 |
BR9915940A (pt) | 2001-09-11 |
HUP0201215A2 (en) | 2002-08-28 |
NO20012737D0 (no) | 2001-06-01 |
IS5943A (is) | 2001-05-15 |
IL143094A0 (en) | 2002-04-21 |
JP2006166920A (ja) | 2006-06-29 |
BG105599A (en) | 2002-02-28 |
CA2350597A1 (en) | 2000-06-08 |
NO20012737L (no) | 2001-07-09 |
PL348310A1 (en) | 2002-05-20 |
CN1329493A (zh) | 2002-01-02 |
ZA200104210B (en) | 2003-02-24 |
AU1290700A (en) | 2000-06-19 |
JP2002531396A (ja) | 2002-09-24 |
HK1041644A1 (zh) | 2002-07-19 |
KR20010086073A (ko) | 2001-09-07 |
OA11722A (en) | 2005-01-25 |
EA200100502A1 (ru) | 2001-12-24 |
TR200101549T2 (tr) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU35401A (sh) | POSTUPCI I PREPARATI ZA USPOSTAVLJANJE UJEDNAČENE STABILNOSTI PROTEINA IZ p53 FAMILIJE | |
YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
MX9702865A (es) | Agentes estrogenicos. | |
AP2001002187A0 (en) | Piperidines as CCR5 modulators. | |
HUP0103633A2 (hu) | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
NO20022251L (no) | Interferon-gamma-konjugater | |
AU3213993A (en) | Tetrahydropyrimidine derivatives and pharmaceutical compositions containing them | |
EP1155121A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING SERUM CHOLESTEROL | |
DE69428334D1 (de) | Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen | |
AU2744200A (en) | Determining protein function and interaction from genome analysis | |
NL1008373A1 (nl) | Stabilisatormengsel voor organische materialen. | |
IL141080A0 (en) | Disubstituted maleimide derivatives and pharmaceutical compositions containing the same | |
HUP9901389A3 (en) | Piperidine and pyrrolidine derivatives acting for the central nervous system, pharmaceutical compositions containing these compounds, preparation and use thereof | |
WO2001042243A3 (en) | Protein kinase inhibitors | |
ATE213944T1 (de) | Verwendung von immunomodulatoren | |
WO2000078795A3 (en) | Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) | |
NO20000519L (no) | 2-acylaminopropanaminer som takykininreseptorantagonister | |
DK0838469T3 (da) | 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser | |
DE69810513D1 (de) | Mimetika von beta-faltblatt und verfahren zur verwendung davon | |
ATE250427T1 (de) | Zusammensetzungen und deren verwendung zur hemmung von angiogenese | |
NO20013878D0 (no) | (1-fenacy-3-fenyl-3-piperidylety1)piperidin-derivater, fremgangsmate for fremstilling derav og farmasoytiske preparaterinneholdende de samme | |
HUP0203534A3 (en) | Use of pharmaceutical compositions containing triazinone compounds for treating diseases resulting from infestation with parasitic protozoans | |
AU3455000A (en) | Composition for decomposing protein | |
NO990675L (no) | 11-acetyl-12,13-dioksabisyklo[8.2.1.]-tridekenonderivater, fremgangsmåter for deres fremstilling, samt legemidler inneholdende slike forbindelser |